A recent study by Böhnke et al. involved the synthesis of mono- and multimeric (di-, tri-, and tetramers) PSMA-targeting small molecules with modified carboxylated HOPO for the treatment of PCa 134. The gene discussed is FOLH1; the disease is posterior cortical atrophy.